Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of ($0.41), $0.33 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $31.7 million versus the consensus estimate of $28.79 million.

“Our first fiscal quarter of 2021 was an especially active time, as we advanced and expanded our wholly-owned pipeline. In HBV, not only did we advance our two ongoing Phase 1b trials of EDP-514, but we also broadened our program with the introduction of EDP-721, a novel HBV RNA destabilizer. We believe that an all-oral regimen of EDP-514, EDP-721 and a nucleos(t)ide reverse transcriptase inhibitor has the potential to lead to a functional cure. We anticipate having preliminary data in our two existing HBV trials in the second quarter of 2021, with a Phase 1 study of EDP-721 on track to initiate mid-year,” stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals.

“We also made meaningful progress on our RSV franchise, initiating an RSV L-protein inhibitor discovery effort centered on potent nanomolar leads active against both RSV-A and RSV-B. Further, we initiated the Phase 2b RSVTx study evaluating EDP-938 in adult hematopoietic cell transplant recipients with RSV, and remain on track to initiate the Phase 2 RSVPEDs study of EDP-938 in pediatric patients with RSV this quarter. Meanwhile, we are in the process of expanding clinical sites for RSVP in Europe and Asia Pacific, so that we are ready when RSV re-emerges. Additionally, we are making significant progress in our discovery efforts in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19), with the goal of identifying two clinical candidates this year from among our hMPV, COVID-19 and RSV discovery programs. Importantly, our strategy for COVID-19 involves targeting mechanisms that should be effective against emerging spike protein variants,” continued Dr. Luly.

“Finally, our non-alcoholic steatohepatitis (NASH) program is progressing with the ARGON-2 trial of EDP-305 and the Phase 1 study of EDP-297 ongoing, and we look forward to having valuable insights around mid-year to inform next steps for our NASH program. Looking ahead, we believe the upcoming year will be important for Enanta, as we progress through numerous milestones across our entire pipeline.”

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.